Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06494579 · ClinicalTrials.gov registry record · Phase 1
Lamivudine for Solid Tumors
A Phase 1 study of Relapsed/Refractory Solid Tumors, sponsored by Thomas Marron.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06494579 is a Phase 1 study of Relapsed/Refractory Solid Tumors that is active but no longer recruiting, run by Thomas Marron. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06494579, a Phase 1 study of Relapsed/Refractory Solid Tumors, is active but no longer recruiting, sponsored by Thomas Marron.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Single arm, set dose clinical trial of Lamivudine for Relapsed Refractory Solid Tumors. Accrual 6-24 patients, within 2 years, study completion within 3 years at Mount Sinai Health System. Primary Objective: For Phase 1b to determine the safety and tolerability of Lamivudine with continued PD-(L)1 blockade for patients with relapsed/refractory metastatic solid tumors that have progressed on standard PD-(L)1 blockade. For Phase 2, to determine the effect of adding lamivudine to PD-(L)1 blocking agents in patients with relapsed/refractory solid tumors that have progressed on prior PD-(L)1 agents Secondary Objectives (Phase 1b and 2) Assess 1) Safety and Tolerability, 2) Best overall response rate (BORR), 3) Progression-free survival (PFS), 4) Overall survival (OS) and 5) Duration of response following addition of lamivudine to standard PD-(L)1 blocking agents, 6) Disease control rate (DCR).
Conditions Studied
Interventions
- DRUG Lamivudine
- DRUG PD-L1 Blocker
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-09-26 |
| Est. Completion | 2026-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06494579
The ClinicalTrials.gov registry entry for NCT06494579 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Marron, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Lamivudine is the first listed.
NCT06494579 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06494579 about?
NCT06494579 is a clinical study titled "Lamivudine for Solid Tumors". Single arm, set dose clinical trial of Lamivudine for Relapsed Refractory Solid Tumors. Accrual 6-24 patients, within 2 years, study completion within 3 years at Mount Sinai Health System. Primary Objective: For Phase 1b to determine the safety and tolerability of Lamivudine with continued PD-(L)...
What is the current status of trial NCT06494579?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-09-26. Estimated completion is 2026-07-28.
What conditions does trial NCT06494579 study?
This clinical trial studies the following conditions: Relapsed/Refractory Solid Tumors.
What interventions are being tested in trial NCT06494579?
The interventions under investigation include: Lamivudine (DRUG), PD-L1 Blocker (DRUG).
Who is sponsoring clinical trial NCT06494579?
This trial is sponsored by Thomas Marron, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06494579 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.